Bio­haven lands pri­or­i­ty re­view on sec­ond-chance ap­pli­ca­tion for neu­rode­gen­er­a­tive drug

Bio­haven’s ex­per­i­men­tal drug tro­r­ilu­zole for the rare, neu­rode­gen­er­a­tive dis­ease spin­ocere­bel­lar atax­ia will get a pri­or­i­ty re­view from the FDA, af­ter the com­pa­ny pre­sent­ed ad­di­tion­al re­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER